Epresivir - Westlake Pharma
Alternative Names: WPV-01Latest Information Update: 17 Jun 2024
At a glance
- Originator Westlake University
- Developer Westlake Pharma
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 26 Jul 2023 Westlake Pharmaceuticals completed a phase-I trial in COVID-2019 infections (In volunteers) in China (PO) (NCT06205329)
- 03 Jul 2023 Westlake Pharmaceuticals completes phase-II clinical trials in COVID-2019 infections in China (PO) (NCT05752175)
- 14 Jun 2023 Phase-III clinical trials in COVID-2019 infections in China (PO) (NCT06197217)